Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
03/08/2023 | CODEXIS, INC. | CDXS | Sale | Common Stock | 27k | $4.56 | $122.9k | | 02/08/2023 |
03/07/2023 | CODEXIS, INC. | CDXS | Sale | Common Stock | 28.1k | $4.60 | $129.3k | | 02/08/2023 |
02/21/2023 | CODEXIS, INC. | CDXS | Grant | Common Stock | 112.5k | $0.00 | $0 | | 02/21/2023 |
02/21/2023 | CODEXIS, INC. | CDXS | Grant | Stock Option (Right to Buy) | 337.5k | $5.44 | $1.8M | | 02/21/2023 |
02/08/2023 | CODEXIS, INC. | CDXS | Grant | Common Stock | 289k | $0.00 | $0 | | 02/08/2023 |
08/01/2022 | CODEXIS, INC. | CDXS | Grant | Stock Option (Right to Buy) | 700k | $6.73 | $4.7M | | 08/01/2022 |
07/01/2022 | Sierra Oncology, Inc. | SRRA | Disposition | Common Stock | 5k | $55.00 | $275k | | 07/01/2022 |
07/01/2022 | Sierra Oncology, Inc. | SRRA | Disposition | Stock Option (right to buy) | 520k | $14.03 | $7.3M | | 07/01/2022 |
07/01/2022 | Sierra Oncology, Inc. | SRRA | Disposition | Stock Option (right to buy) | 260k | $12.15 | $3.2M | | 07/01/2022 |
07/01/2022 | Sierra Oncology, Inc. | SRRA | Disposition | Stock Option (right to buy) | 92k | $16.73 | $1.5M | | 07/01/2022 |
07/01/2022 | Sierra Oncology, Inc. | SRRA | Disposition | Stock Option (right to buy) | 165k | $31.54 | $5.2M | | 07/01/2022 |
06/17/2022 | Sierra Oncology, Inc. | SRRA | Grant | Stock Option (Right to Buy) | 65k | $12.15 | $789.8k | | 06/17/2022 |
06/14/2022 | CODEXIS, INC. | CDXS | Grant | Common Stock | 11.3k | $0.00 | $0 | | 06/14/2022 |
03/14/2022 | Sierra Oncology, Inc. | SRRA | Grant | Stock Option (Right to Buy) | 165k | $31.54 | $5.2M | | 03/14/2022 |
01/28/2022 | Sierra Oncology, Inc. | SRRA | Grant | Stock Option (Right to Buy) | 65k | $12.15 | $789.8k | | 01/28/2022 |
06/15/2021 | CODEXIS, INC. | CDXS | Grant | Common Stock | 4.8k | $0.00 | $0 | | 06/15/2021 |
05/19/2021 | Sierra Oncology, Inc. | SRRA | Purchase | Common Stock | 5k | $17.83 | $89.2k | | 05/19/2021 |
03/15/2021 | Sierra Oncology, Inc. | SRRA | Grant | Stock Option (Right to Buy) | 92k | $16.73 | $1.5M | | 03/15/2021 |
06/16/2020 | CODEXIS, INC. | CDXS | Grant | Common Stock | 17.9k | $0.00 | $0 | | 06/16/2020 |
06/01/2020 | Sierra Oncology, Inc. | SRRA | Grant | Stock Option (right to buy) | 520k | $14.03 | $7.3M | | 06/01/2020 |
05/18/2020 | SANGAMO THERAPEUTICS, INC | SGMO | Grant | Common Stock | 10k | $0.00 | $0 | | 05/18/2020 |
05/18/2020 | SANGAMO THERAPEUTICS, INC | SGMO | Grant | Stock Option (Right to Buy) | 20k | $10.46 | $209.2k | | 05/18/2020 |
05/18/2020 | SANGAMO THERAPEUTICS, INC | SGMO | Grant | Stock Option (Right to Buy) | 15k | $10.46 | $156.9k | | 05/18/2020 |
05/18/2020 | SANGAMO THERAPEUTICS, INC | SGMO | Grant | Common Stock | 2.5k | $0.00 | $0 | | 05/18/2020 |
03/19/2020 | SANGAMO THERAPEUTICS, INC | SGMO | Exercise | Stock Option (Right-to-Buy) | 35k | $5.42 | $189.7k | | 03/19/2020 |
03/19/2020 | SANGAMO THERAPEUTICS, INC | SGMO | Sale | Common Stock | 35k | $6.00 | $210k | | 03/19/2020 |
03/16/2020 | SANGAMO THERAPEUTICS, INC | SGMO | Sale | Common Stock | 15k | $6.02 | $90.3k | | 03/16/2020 |
03/16/2020 | SANGAMO THERAPEUTICS, INC | SGMO | Exercise | Stock Option (Right-to-Buy) | 15k | $5.42 | $81.3k | | 03/16/2020 |
06/10/2019 | SANGAMO THERAPEUTICS, INC | SGMO | Grant | Stock Option (Right to Buy) | 15k | $9.38 | $140.7k | | 06/10/2019 |
06/10/2019 | SANGAMO THERAPEUTICS, INC | SGMO | Grant | Common Stock | 2.5k | $0.00 | $0 | | 06/10/2019 |
06/11/2018 | Aimmune Therapeutics, Inc. | AIMT | Sale | Common Stock, $0.0001 par value | 29.5k | $30.83 | $908.3k | | 06/11/2018 |
06/11/2018 | Aimmune Therapeutics, Inc. | AIMT | Exercise | Stock Option (right to buy) | 29.5k | $3.02 | $89k | | 06/11/2018 |
06/11/2018 | SANGAMO THERAPEUTICS, INC | SGMO | Grant | Common Stock | 2.5k | $0.00 | $0 | | 06/11/2018 |
06/11/2018 | SANGAMO THERAPEUTICS, INC | SGMO | Grant | Stock Option (Right to Buy) | 15k | $15.65 | $234.8k | | 06/11/2018 |
06/08/2018 | Aimmune Therapeutics, Inc. | AIMT | Exercise | Stock Option (right to buy) | 42.1k | $3.02 | $127.2k | | 06/06/2018 |
|